Eton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $52.00 at HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON) had its price objective raised by HC Wainwright from $37.00 to $52.00 in a research note issued to investors on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

ETON has been the subject of several other research reports. Wall Street Zen downgraded shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, December 13th. Zacks Research upgraded Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Craig Hallum upped their price objective on Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday. B. Riley Financial increased their price objective on Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $39.33.

Eton Pharmaceuticals Stock Up 7.5%

ETON stock opened at $22.32 on Friday. The company has a market cap of $598.58 million, a price-to-earnings ratio of -123.99 and a beta of 1.19. The company has a fifty day moving average price of $16.72 and a 200 day moving average price of $17.38. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.63 and a quick ratio of 1.25. Eton Pharmaceuticals has a 12 month low of $11.09 and a 12 month high of $23.00.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings data on Thursday, March 19th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.07). The business had revenue of $21.28 million for the quarter, compared to analysts’ expectations of $20.58 million. Eton Pharmaceuticals had a negative return on equity of 2.66% and a negative net margin of 5.75%. Sell-side analysts expect that Eton Pharmaceuticals will post -0.14 earnings per share for the current year.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of large investors have recently bought and sold shares of ETON. Deutsche Bank AG raised its holdings in shares of Eton Pharmaceuticals by 4.9% in the 4th quarter. Deutsche Bank AG now owns 18,249 shares of the company’s stock worth $309,000 after purchasing an additional 850 shares during the period. Intech Investment Management LLC grew its holdings in shares of Eton Pharmaceuticals by 11.1% during the 4th quarter. Intech Investment Management LLC now owns 12,421 shares of the company’s stock worth $210,000 after purchasing an additional 1,244 shares during the period. Man Group plc grew its holdings in shares of Eton Pharmaceuticals by 6.0% during the 2nd quarter. Man Group plc now owns 23,754 shares of the company’s stock worth $338,000 after purchasing an additional 1,350 shares during the period. State of Alaska Department of Revenue acquired a new stake in Eton Pharmaceuticals during the 3rd quarter worth approximately $30,000. Finally, Quarry LP acquired a new stake in Eton Pharmaceuticals during the 3rd quarter worth approximately $37,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Trending Headlines about Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Several brokerages raised price targets and reiterated buy ratings (HC Wainwright to $52, B. Riley to $31, Craig Hallum to $35), increasing upside expectations and driving bullish investor sentiment. Analyst Upgrades
• Positive Sentiment: Eton acquired U.S. rights to HEMANGEOL, expanding its commercial portfolio in a specialty/rare-disease area and creating a clearer near-term revenue pathway. Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
• Positive Sentiment: Market commentary highlights a meaningful consensus upside — Zacks notes analysts’ mean targets imply roughly a 49% rally — reinforcing the bullish narrative from upgraded targets. Does Eton Pharmaceuticals Have the Potential to Rally 49.25%?
• Neutral Sentiment: Earnings call and company commentary emphasized record revenue growth and commercial progress, which supports the growth story but did not fully offset margin pressures. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Reported short-interest data for March appears anomalous/flat (0 shares reported and a 0.0 days-to-cover), so it’s unlikely to be a material driver of today’s move. (Data looks unreliable.)
• Negative Sentiment: Q4 results: revenue beat slightly ($21.28M vs. $20.58M est.) but EPS missed ($0.05 vs. $0.12 est.); the company still reports negative net margin and negative ROE, raising profitability concerns. Eton Pharmaceuticals Reports Q4 & Full-Year 2025 Results
• Negative Sentiment: Analyst coverage also flagged the EPS miss in headlines (Zacks: earnings lag estimates), which could cap near-term sentiment until margins improve. Eton Q4 Earnings Lag Estimates

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.